登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science，1月29日，Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2021-02-23

  • Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

    View ORCID ProfileAlexander Muik1, View ORCID ProfileAnn-Kathrin Wallisch1, View ORCID ProfileBianca Sänger1, View ORCID ProfileKena A. Swanson2, View ORCID ProfileJulia Mühl1, Wei Chen2, Hui C...

    Science 29 Jan 2021:

    eabg6105

    DOI: 10.1126/science.abg6105

    Abstract

    Recently, a new SARS-CoV-2 lineage called B.1.1.7 (variant of concern: VOC 202012/01) emerged in the United Kingdom that was reported to spread more efficiently and faster than other strains. This variant has an unusually large number of mutations with 10 amino acid changes in the spike protein, raising concerns that its recognition by neutralizing antibodies may be affected. Here, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.

  • 原文来源：https://science.sciencemag.org/content/early/2021/01/28/science.abg6105
126浏览量
原文链接
相关报告

  • 《Science，3月12日，Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-03-22
    • Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera View ORCID ProfileAlexander Muik1, View ORCID ProfileAnn-Kathrin Wallisch1, View ORCID ProfileBianca Sänger1, View ORCID ProfileKena A. Swanson2, View ORCID ProfileJulia Mühl1, Wei Chen2, Hui Cai2, View ORCID ProfileDaniel Maurus1, Ritu Sarkar2, View ORCID ProfileÖzlem Türeci1, View ORCID ProfilePhilip R. Dormitzer2, View ORCID ProfileU?ur ?ahin1,3,* See all authors and affiliations Science  12 Mar 2021: Vol. 371, Issue 6534, pp. 1152-1153 DOI: 10.1126/science.abg6105 Abstract Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA–based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
    82浏览量
    原文链接

  • 《Science，1月18日，Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera》
    • 来源专题：COVID-19科研动态监测
    • 编译者：YUTING
    • 发布时间：2022-02-08
    • The globally-circulating SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) has a large number of mutations especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan, Beta, Delta, or Omicron pseudoviruses with sera of 51 participants that received two or three doses of the mRNA-based COVID-19 vaccine BNT162b2. Following two doses, sera had >22-fold reduced neutralizing titers against Omicron compared to Wuhan pseudovirus. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold compared to two doses, with titers similar to Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed using live SARS-CoV-2 in a subset of participants. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19.
    168浏览量
    原文链接